Anna Galligan

Dr. Anna Galligan

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2019 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
MKMervyn Kyi
Mervyn Kyi
PCPeter G. Colman
Peter G. Colman
PWPaul R. Wraight
Paul R. Wraight
JRJane Reid
Jane Reid
AGAlexandra Gorelik
Alexandra Gorelik
SFSpiros Fourlanos
Spiros Fourlanos
OBJECTIVE To investigate if early electronic identification and bedside management of inpatients with diabetes improves glycemic control in noncritical care. RESEARCH DESIGN AND METHODS We investigated a proactive or early intervention model of care (whereby an inpatient diabetes team electronically identified individuals with diabetes and aimed to provide bedside management within 24 h of admission) compared with usual care (a referral-based consultation service). We conducted a cluster randomized trial on eight wards, consisting of a 10-week baseline period (all clusters received usual care) followed by a 12-week active period (clusters randomized to early intervention or usual care). Outcomes were adverse glycemic days (AGDs) (patient-days with glucose 15 mmol/L [270 mg/dL]) and adverse patient outcomes. RESULTS We included 1,002 consecutive adult inpatients with diabetes or new hyperglycemia. More patients received specialist diabetes management (92% vs. 15%, P < 0.001) and new insulin treatment (57% vs. 34%, P = 0.001) with early intervention. At the cluster level, incidence of AGDs decreased by 24% from 243 to 186 per 1,000 patient-days in the intervention arm (P < 0.001), with no change in the control arm. At the individual level, adjusted number of AGDs per person decreased from a mean 1.4 (SD 1.6) to 1.0 (0.9) days (−28% change [95% CI −45 to −11%], P = 0.001) in the intervention arm but did not change in the control arm (1.8 [2.0] to 1.5 [1.8], −9% change [−25 to 6%], P = 0.23). Early intervention reduced overt hyperglycemia (55% decrease in patient-days with mean glucose >15 mmol/L, P < 0.001) and hospital-acquired infections (odds ratio 0.20 [95% CI 0.07–0.58], P = 0.003). CONCLUSIONS Early identification and management of inpatients with diabetes decreased hyperglycemia and hospital-acquired infections.

1 May 2023 in Radiology
Verified
Journal Article
Closed access
AIAmir Iravani
Amir Iravani
RWRoslyn Wallace
Roslyn Wallace
SLSerigne N. Lo
Serigne N. Lo
AGAnna Galligan
Anna Galligan
AWAlison M. Weppler
Alison M. Weppler
Shahneen K. SandhuShahneen K. Sandhu
Shahneen K. Sandhu
Background Despite improved response to combined ipilimumab and nivolumab (hereafter, IpiNivo) treatment for advanced melanoma, many patients exhibit primary or acquired resistance. This, combined with high risk of immune-related adverse events, makes identifying markers predictive of outcomes desirable. Purpose To investigate the prognostic value of fluorine 18 (18F) fluorodeoxyglucose (FDG) PET/CT parameters at baseline and as part of response monitoring in patients with advanced melanoma undergoing IpiNivo treatment. Materials and Methods This was a single-center retrospective study of adult patients with melanoma who received IpiNivo. Baseline FDG PET/CT parameters that included metabolic tumor volume (MTV), tumor stage, mutation status, Eastern Cooperative Oncology Group performance score, lactate dehydrogenase level, and treatment line were correlated with overall survival in univariable and multivariable Cox regression analyses. Treatment response as determined with FDG PET/CT was correlated with overall survival. Results In total, 122 patients (median age, 61 years [IQR, 51-69 years]; 89 men) were included; 78% (95 of 122) had an Eastern Cooperative Oncology Group score of 0, 52% (45 of 86) had an elevated lactate dehydrogenase level, 39% (48 of 122) had a metastatic stage of M1c and 45% (55 of 122) M1d, 45% (55 of 122) had BRAF V600E/K mutation, and the median MTV was 42 mL. Patients with a higher than median MTV at baseline FDG PET/CT had a lower 12-month survival rate compared with those with a lower than median MTV (43% [95% CI: 32, 58] vs 66% [95% CI: 55, 79], P < .001). In multivariable analysis, higher versus lower than median MTV, Eastern Cooperative Oncology Group performance scores of 1-2 versus 0, and subsequent versus first-line IpiNivo treatment were independently associated with overall survival (hazard ratio [HR]: 1.68 [95% CI: 1.02, 2.78], P = .04; 3.1 [95% CI: 1.8, 5.4], P < .001; and 11.2 [95% CI: 3.4, 37.1], P = .002, respectively). The 12-month overall survival rate was lower in patients with progressive disease than in those without progression (35% [95% CI: 24, 51] vs 90% [95% CI: 83, 99]; HR, 7.3 [95% CI: 3.9, 13.3]; P < .001). Conclusion Baseline fluorine 18 fluorodeoxyglucose PET/CT metabolic tumor volume was an independent prognostic marker in patients with advanced melanoma who received ipilimumab and nivolumab treatment. © RSNA, 2023 Supplemental material is available for this article.

16 June 2018 in Diabetic Medicine
Verified
Journal Article
Closed access
PDF file
AGAnna Galligan
Anna Galligan
WXW. Xu
W. Xu
SFS. Fourlanos
S. Fourlanos
ANA. Nankervis
A. Nankervis
CCC. Chiang
C. Chiang
PCP. G. Colman
P. G. Colman

11 December 2023 in Cancers
Verified
Journal Article
Open access
PDF file
AGAnna Galligan
Anna Galligan
RWRoslyn Wallace
Roslyn Wallace
BKBalasubramanian Krishnamurthy
Balasubramanian Krishnamurthy
TKThomas W. H. Kay
Thomas W. H. Kay
NSNirupa Sachithanandan
Nirupa Sachithanandan
AIAmir Iravani
Amir Iravani
Background: FDG-PET/CT used for immune checkpoint inhibitor (ICI) response assessment can incidentally identify immune-related adverse events (irAEs), including thyroiditis. This study aimed to correlate the time course of FDG-PET/CT evidence of thyroiditis with clinical and biochemical evolution of thyroid dysfunction. Methods: A retrospective review was performed by two independent blinded nuclear medicine physicians (NMPs) of thyroidal FDG uptake in 127 patients who underwent PET/CT between January 2016 and January 2019 at baseline and during treatment monitoring of combination ICI therapy for advanced melanoma. Interobserver agreement was assessed and FDG-PET/CT performance defined by a receiver-operating characteristic (ROC) curve using thyroid function tests (TFTs) as the standard of truth. Thyroid maximum standardized uptake value (SUVmax) and its temporal changes with respect to the longitudinal biochemistry were serially recorded. Results: At a median of 3 weeks after commencing ICI, 43/127 (34%) had a diagnosis of thyroiditis established by abnormal TFTs. FDG-PET/CT was performed at baseline and at a median of 11 weeks (range 3–32) following the start of therapy. ROC analysis showed an area under the curve of 0.87 (95% CI 0.80, 0.94) for FDG-PET/CT for detection of thyroiditis with a positive predictive value of 93%. Among patients with biochemical evidence of thyroiditis, those with a positive FDG-PET/CT were more likely to develop overt hypothyroidism (77% versus 35%, p < 0.01). In the evaluation of the index test, there was an almost perfect interobserver agreement between NMPs of 93.7% (95% CI 89.4–98.0), kappa 0.83. Conclusion: Increased metabolic activity of the thyroid on routine FDG-PET/CT performed for tumoral response of patients undergoing ICI therapy is generally detected well after routine biochemical diagnosis. Elevation of FDG uptake in the thyroid is predictive of overt clinical hypothyroidism and suggests that an ongoing robust inflammatory response beyond the initial thyrotoxic phase may be indicative of thyroid destruction.

12 December 2019 in Diabetes Care
Verified
Journal Article
Open access
PDF file
AGAnna Galligan
Anna Galligan
BKBalasubramanian Krishnamurthy
Balasubramanian Krishnamurthy
TKThomas W. Kay
Thomas W. Kay

26 February 2026 in JMIR Research Protocols
Verified
Journal Article
Open access
KWKate Waller
Kate Waller
RORajna Ogrin
Rajna Ogrin
QNQuoc Cuong Ngo
Quoc Cuong Ngo
BPBarbara Polus
Barbara Polus
SHSamantha Hanna
Samantha Hanna
Dinesh K. KumarDinesh K. Kumar
Dinesh K. Kumar
Background: Diabetes-related foot ulcers (DFUs) are common in people with diabetes and a major cause of poor quality of life and disability. If not treated in a timely and appropriate way, DFUs may result in prolonged hospitalization and amputation. Currently, methods to predict the healing trajectory of DFUs lack accuracy. Thermal imaging has been proposed to overcome these limitations but has been unable to accurately predict delayed healing of DFUs in the early stages of ulcer management. This project aims to ascertain whether textural analysis of a thermal image can predict the healing trajectory of DFUs. Objective: The study aims (1) to co-design an accurate, fast, easy-to-use, computer-aided, nontouch test to predict DFU healing trajectory using texture analysis of thermal imaging that is fit for purpose and acceptable to both, those being tested and users of the device and (2) to validate whether textural analysis of thermal images can accurately predict healing of DFUs at week 12 from an image taken at week 1. Methods: This project will be undertaken in 2 phases: Phase 1, co-design and development of the software prototype; and Phase 2, technology validation. Phase 1 requires a participatory action, co-design approach, engaging clinicians and biomedical engineers in a facilitated focus group and email communication. Interviews with adults living with diabetes and a DFU or who have a history of a DFU will be undertaken to understand their information needs about the device and its findings. Phase 2 will be a longitudinal observational study of 120 adults living with a DFU over a 12-week period. Demographic and other data that have been shown to impact wound healing will be collected at baseline, including participant age, gender, wound size, wound duration, and biomedical markers. Thermal and standard red, green, and blue images will be taken at weeks 1, 2, and 12. Wound textural features will be entered into a Bayesian neural network to identify the healing trajectory. Results: Phase 1 has been completed with biomedical engineers and clinicians from High Risk Foot Services at 2 hospitals in Melbourne, Australia. Nine clinicians participated in a co-design focus group, and 6 clinicians communicated via email. Four themes were identified: insights for sector use, how to document and use the device, legal implications, and workflow requirements. Interviews with 4 people living with diabetes were undertaken, with data to be analyzed thematically. Phase 2 data collection will be completed by April 2026. Conclusions: The study aims to co-design, test, and validate an accurate, feasible, and acceptable device to predict the healing of DFUs at week 12 from an image taken at week 1. This has the potential to assist clinicians in making informed and timely decisions for instigating adjuvant therapies, thereby improving healing and preventing lower extremity amputations.